SMSPHARMA — SMS Pharmaceuticals Share Price
Last trade - 00:00- IN₹47.58bn
- IN₹50.69bn
- IN₹8.87bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 41.52 | ||
| PEG Ratio (f) | 5.12 | ||
| EPS Growth (f) | 8.82% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.65 | ||
| Price to Tang. Book | 5.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.9 | ||
| EV to EBITDA | 26.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.44% | ||
| Return on Equity | 14.88% | ||
| Operating Margin | 15.6% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 5,198.74 | 5,220.51 | 7,092.63 | 7,827.48 | 8,868.71 | 10,022 | 11,425 | 9.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -0.49 | n/a | n/a | +38.68 | +36.73 | +1.3 | +13.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Directors
- Ramesh Potluri CHM (63)
- Shravan Kudaravalli NID
- Vamsi Potluri EDR (36)
- Lakshmi Tammineedi CFO
- Trilok Potluri NED
- Sunkara Prasad NED
- Suresh Gangavarapu NID
- Bolleni Sree NID (64)
- Manohar Mollama CCO
- Last Annual
- March 31st, 2026
- Last Interim
- September 30th, 2026
- Incorporated
- December 14th, 1987
- Public Since
- February 25th, 2007
- No. of Shareholders
- 32,397
- No. of Employees
- 1,617
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 93,652,030
- Address
- Plot No.72,, HYDERABAD, 500034
- Web
- https://smspharma.com/
- Phone
- +91 4025259999
- Auditors
- SURYANARAYANA & SURESH
Latest News for SMSPHARMA
Upcoming Events for SMSPHARMA
Q3 2027 SMS Pharmaceuticals Ltd Earnings Release
Similar to SMSPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 13:21 UTC, shares in SMS Pharmaceuticals are trading at IN₹508.05. This share price information is delayed by 15 minutes.
Shares in SMS Pharmaceuticals last closed at IN₹508.05 and the price had moved by +74.95% over the past 365 days. In terms of relative price strength the SMS Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +78.1% over the past year.
The overall consensus recommendation for SMS Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe SMS Pharmaceuticals dividend yield is 0.08% based on the trailing twelve month period.
Last year, SMS Pharmaceuticals paid a total dividend of IN₹0.40, and it currently has a trailing dividend yield of 0.08%. We do not have any data on when SMS Pharmaceuticals is to next pay dividends.
We do not have data on when SMS Pharmaceuticals is to next pay dividends. The historic dividend yield on SMS Pharmaceuticals shares is currently 0.08%.
To buy shares in SMS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹508.05, shares in SMS Pharmaceuticals had a market capitalisation of IN₹47.58bn.
Here are the trading details for SMS Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SMSPHARMA
Based on an overall assessment of its quality, value and momentum SMS Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SMS Pharmaceuticals is IN₹382.00. That is 24.81% below the last closing price of IN₹508.05.
Analysts covering SMS Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹11.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SMS Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +19.14%.
As of the last closing price of IN₹508.05, shares in SMS Pharmaceuticals were trading +27.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SMS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 41.52. The shares last closed at IN₹508.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SMS Pharmaceuticals' management team is headed by:
- Ramesh Potluri - CHM
- Shravan Kudaravalli - NID
- Vamsi Potluri - EDR
- Lakshmi Tammineedi - CFO
- Trilok Potluri - NED
- Sunkara Prasad - NED
- Suresh Gangavarapu - NID
- Bolleni Sree - NID
- Manohar Mollama - CCO